ERBB2 and breast carcinoma: Following this era of clinical advances, we found it critical to characterize a cohort of breast cancer patients with HER2-low tumors from a national cancer reference center in Colombia, aiming to shed light on important clinical and pathological differences within this subset of patients when compared to both well-characterized HER2-negative and HER2-positive groups, hoping that our results will contribute to a more comprehensive understanding of the clinical features of this disease in the Colombian population.